Mara Khaylomskaya, MD
Internal Medicine · New York, NYNPI 1417992322
Payments from drug & device makers
Across 672 payments — averaging $38.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- GSK$3K
- Amgen$2K
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- plus $9K from 30 others
What the payments were for
- Food & beverage$25,838100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 166 | $6,991 |
| GSK | 56 | $2,502 |
| Amgen(2 entities) | 62 | $2,213 |
| AstraZeneca | 45 | $1,912 |
| Boehringer Ingelheim | 19 | $1,696 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 77 | $1,397 |
| Lilly USA, LLC | 22 | $1,340 |
| Amarin Pharma, Inc. | 19 | $1,017 |
| Novo Nordisk | 22 | $963 |
| Esperion Therapeutics, Inc. | 29 | $961 |
| E.r. Squibb & Sons, L.L.C. | 9 | $700 |
| Ardelyx, Inc. | 11 | $543 |
| Aimmune Therapeutics, Inc. | 12 | $511 |
| Alkermes, Inc. | 8 | $411 |
| Axsome Therapeutics, Inc. | 9 | $397 |
| Novartis | 11 | $242 |
| Sumitomo Pharma America, Inc. | 11 | $238 |
| Merck | 14 | $225 |
| Arbor Pharmaceuticals, Inc. | 11 | $210 |
| Nestle Healthcare Nutrition Inc. | 10 | $208 |
| Endo Pharmaceuticals Inc. | 12 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $157 |
| Sunovion Pharmaceuticals Inc. | 6 | $145 |
| Pfizer | 7 | $132 |
| Bayer | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $110 |
| Bristol Myers Squibb | 3 | $63 |
| Johnson & Johnson | 2 | $50 |
| Sanofi-aventis U.S. LLC | 1 | $31 |
| CSL Behring | 1 | $30 |
| Vistapharm, Inc. | 2 | $28 |
| Vivus LLC | 1 | $20 |
| Shield Therapeutics Inc | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,838 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 195 | $267,446 |
| CreonLipase/Protease/Amylase | 202 | $247,859 |
| EliquisApixaban | 297 | $218,877 |
| Diclofenac Sodium | 538 | $209,977 |
| VascepaIcosapent Ethyl | 383 | $150,556 |
| LinzessLinaclotide | 207 | $146,154 |
| FarxigaDapagliflozin Propanediol | 156 | $128,906 |
| JanumetSitagliptin Phos/Metformin Hcl | 172 | $115,258 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 178 | $113,553 |
| MyrbetriqMirabegron | 192 | $103,880 |
| GemtesaVibegron | 193 | $96,747 |
| NeuproRotigotine | 117 | $95,210 |
| JardianceEmpagliflozin | 88 | $79,986 |
| ZtlidoLidocaine | 170 | $68,952 |
| XifaxanRifaximin | 24 | $65,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis, Namzaric, Vraylar | $6,991 | $520,337553 claims |
| Aimmune Therapeutics, Inc.Zenpep | $511 | $267,446195 claims |
| PfizerEliquis, Nurtec Odt | $132 | $254,259321 claims |
| AstraZenecaFarxiga | $1,912 | $128,906156 claims |
| MerckJanumet | $225 | $115,258172 claims |
| GSKTrelegy Ellipta | $2,502 | $113,553178 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,397 | $106,29590 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $238 | $96,747193 claims |
| Boehringer IngelheimJardiance | $1,696 | $79,98688 claims |
| Novo NordiskOzempic, Rybelsus | $963 | $72,44372 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,340 | $66,90967 claims |
| AmgenProlia | $2,213 | $64,18340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.